Plasma prolactin and breast cancer

Wilson, R. G.; Buchan, Robert; Roberts, M M; Forrest, A. P. M.; Boyns, A. R.; Cole, E.N.; Griffiths, K.

doi:10.1002/1097-0142(197405)33:5<1325::aid-cncr2820330517>3.0.co;2-v

Cited by 47 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In two of these studies, a significant positive association was reported (7,73); no association was observed in two others; and in one a significant inverse association was seen (72). Finally, in four small studies in which premenopausal and postmenopausal women were combined (69,(75)(76)(77), no significant associations were reported. Overall, results from the casecontrol studies have been inconsistent.…”

mentioning

confidence: 94%

The Role of Prolactin in Mammary Carcinoma

et al. 2003

View full text Add to dashboard Cite

The contribution of prolactin (PRL) to the pathogenesis and progression of human breast cancer at the cellular, transgenic, and epidemiological levels is increasingly appreciated. Acting at the endocrine and autocrine/paracrine levels, PRL functions to stimulate the growth and motility of human breast cancer cells. The actions of this ligand are mediated by at least six recognized PRL receptor isoforms found on, or secreted by, human breast epithelium. The PRL/PRL receptor complex associates with and activates several signaling networks that are shared with other members of the cytokine receptor superfamily. Coupled with the recently identified intranuclear function of PRL, these networks are integrated into the in vitro and in vivo actions induced by ligand. These findings indicate that antagonists of PRL/PRL receptor interaction or PRL receptor-associated signal transduction may be of considerable utility in the treatment of human breast cancer.

show abstract

mentioning

confidence: 94%

The Role of Prolactin in Mammary Carcinoma

et al. 2003

View full text Add to dashboard Cite

show abstract

“…A tendency for women with breast cancer to secrete more growth hormone in response to a glucose load has been described by Greenwood, James, * Meggitt, Miller, and Taylor (1968) and Pearson, Llerena, Samaan, and Gonzales (1968), and recently * Murray, Mozaffarian, and Pearson (1972) have also reported increased levels of circulating prolactin in this disease. In our experience the growth hormone response to insulin hypoglycemia was normal in women with advanced malignancy of the breast (Stewart, Benson, Roberts, Forrest, and Greenwood, 1971) Wilson, and Forrest, 1973;Wilson et al, 1973). Recent results using a homologous assay are shown in the table.…”

Section: Human Breast Cancermentioning

confidence: 81%

Hormones and neoplasia

Forrest¹

1974

J Clin Pathol

Self Cite

View full text Add to dashboard Cite

show abstract

“…A tendency for women with breast cancer to secrete more growth hormone in response to a glucose load has been described by Greenwood, James, * Meggitt, Miller, and Taylor (1968) and Pearson, Llerena, Samaan, and Gonzales (1968), and recently * Murray, Mozaffarian, and Pearson (1972) have also reported increased levels of circulating prolactin in this disease. In our experience the growth hormone response to insulin hypoglycemia was normal in women with advanced malignancy of the breast (Stewart, Benson, Roberts, Forrest, and Greenwood, 1971) and circulating prolactin, estimated either by with benign disease of the breast, and those with (Forrest, 1972;Boyns, Cole, Griffiths, Roberts, Buchan, Wilson, and Forrest, 1973;Wilson et al, 1973). Recent results using a homologous assay are shown in the table.…”

Section: Human Breast Cancermentioning

confidence: 91%